Immunoglobulin Fc Fragments

• 

  Subject Areas on Research

  • Activation of human B lymphocytes. XIV. Characterization of the precursor of the pokeweed mitogen-induced anti-sheep red blood cell plaque-forming cell. 
  • Alteration of T-lymphocyte subpopulations in sarcoidosis. 
  • An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques. 
  • Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. 
  • Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. 
  • Binding site on human immunoglobulin G for the affinity ligand HWRGWV. 
  • Changes in oligosaccharide chains of autoantibodies to GRP78 expressed during progression of malignant melanoma stimulate melanoma cell growth and survival. 
  • Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. 
  • Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. 
  • Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques. 
  • Dissection of the protein G B1 domain binding site for human IgG Fc fragment. 
  • Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. 
  • Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. 
  • Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. 
  • Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK. 
  • Exploring variation in binding of Protein A and Protein G to immunoglobulin type G by isothermal titration calorimetry. 
  • Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. 
  • Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis. 
  • Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. 
  • Interleukin-15 receptor blockade in non-human primate kidney transplantation. 
  • K12/SECTM1, an interferon-γ regulated molecule, synergizes with CD28 to costimulate human T cell proliferation. 
  • Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. 
  • LPS-binding IgG arrests actively motile Salmonella Typhimurium in gastrointestinal mucus. 
  • Maternal gatekeepers: How maternal antibody Fc characteristics influence passive transfer and infant protection. 
  • Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. 
  • Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV. 
  • Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. 
  • Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. 
  • Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. 
  • Self-assembling peptide nanofiber HIV vaccine elicits robust vaccine-induced antibody functions and modulates Fc glycosylation. 
  • Suppression of conformational heterogeneity at a protein-protein interface. 
  • Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. 
  • The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge. 
  • The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. 
  • The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen. 
  • Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. 
  • Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.